This medication is primarily prescribed for patients who have previously been treated with other ALK inhibitors such as crizotinib and ceritinib. It is also used in patients who have developed resistance to these earlier treatments. Individuals diagnosed with ALK-positive or ROS1-positive NSCLC are the primary beneficiaries of Lorlatinib therapy.
